Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant

Published:2023-06 Issue:6 Volume:12 Page:
ISSN:2042-6305
Container-title:Journal of Comparative Effectiveness Research
language:en
Short-container-title:J. Comp. Eff. Res.

Author:

Law Ernest H¹^ORCID,Cameron Chris²^ORCID

Affiliation:

1. Director, Value & Evidence, Pfizer, New York, NY 10017, USA

2. Chief Scientific Officer, Global Value & Evidence, EVERSANA, Sydney, Nova Scotia, B1P 1C6, Canada

Funder

Pfizer

Publisher

Becaris Publishing Limited

Subject

Health Policy

Link

https://becarispublishing.com/doi/pdf/10.57264/cer-2023-0009

Reference4 articles.

1. Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points

2. Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer

3. Oncologist and patient preferences for attributes of CDK4/6 inhibitor regimens for the treatment of advanced/metastatic HR positive/HER2 negative breast cancer: discrete choice experiment and best–worst scaling;Maculaitis MC;Patient Prefer. Adherence,2020

4. Implementing shared decision making in the NHS;Elwyn G;Brit. Med. J.,2010

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP